Dana Iovanescu

Dr. Dana Iovanescu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2024 in Medicina
Verified
Journal Article
Open access
PDF file
KOPPANDI OANAKOPPANDI OANA
KOPPANDI OANA
DIDana Iovanescu
Dana Iovanescu
BMBogdan Miutescu
Bogdan Miutescu
AMAlexandru Catalin Motofelea
Alexandru Catalin Motofelea
OJOana Maria Jigău
Oana Maria Jigău
EMEftimie Miuțescu
Eftimie Miuțescu
Background and Objectives: Chronic hepatitis C virus (HCV) infection is intricately linked with dysregulation of lipid metabolism. In particular, cholesterol plays a crucial role in HCV replication. Direct-acting antiviral agents (DAAs) therapy has revolutionized the hepatitis C treatment landscape, achieving high rates of sustained virological response (SVR). However, viral clearance comes with some alterations in lipid-related markers. This prospective study aimed to evaluate the impact of HCV clearance on lipid homeostasis and non-invasive liver fibrosis markers in hepatitis C patients treated with DAAs. Material and Methods: Fifty-two patients with varying degrees of fibrosis treated with DAAs therapy were evaluated at baseline and 24 weeks post-SVR. Lipid profiles and non-invasive liver fibrosis markers were assessed. Results: Our findings revealed an increase in total cholesterol, triglyceride, and LDLc (low-density lipoprotein cholesterol) levels at 24 weeks post-SVR, alongside an improvement in serum liver enzymes. Although improvements in liver stiffness were observed in non-invasive tests, there was an increase in lipid-related markers post-SVR. Conclusions: This suggests a potential increased cardiovascular risk despite improvements in liver function and fibrosis, highlighting the necessity for statin therapy in some cases and extended follow-ups for these patients. These findings underscore the importance of closely monitoring lipid profiles in chronic hepatitis C patients post-SVR, as well as the potential need for statin therapy to mitigate cardiovascular risk. Additionally, extended follow-up is essential to assess long-term outcomes and ensure the optimal management of these patients.

20 May 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
CCCoralia Cotoraci
Coralia Cotoraci
ASAlciona Sasu
Alciona Sasu
EMEftimie Miutescu
Eftimie Miutescu
DIDana Iovanescu
Dana Iovanescu
SGSami Gharbia
Sami Gharbia
Anca HermeneanAnca Hermenean
Anca Hermenean
Chemotherapy and radiation are often accompanied by complications such as intestinal mucositis. The aim of this study was to assess by immunohistochemical assay the consequences of epirubicin-based therapy applied to onco-hematological patients, on the mucosal cells that undergo apoptosis and on the tight junction proteins, immediately before and after a short time of chemotherapy administration. We assessed the protein expression and distribution of the pro-apoptotic Bax, anti-apoptotic Bcl-2 and effector Caspase-3 as key proteins in apoptosis pathways and the changes in immunopositivity of Claudin-1 and ZO-1 tight junction proteins. Results show that the Bcl-2 family is involved in intestinal damage via Caspase-3 dependent apoptosis of epithelial cells. Additionally, the intestinal mucositis activates other injurious pathways through a dramatic drop in Claudin-1 and ZO-1 expressions, contributing for a while to a structural and functional integrity disruption of the intestinal epithelium.

18 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
ADAlina Dolghi
Alina Dolghi
DBDan Alin Brebu
Dan Alin Brebu
ABAda Meda Bugi
Ada Meda Bugi
ANAndreea-Adriana Neamțu
Andreea-Adriana Neamțu
ACAnca-Maria Căpraru
Anca-Maria Căpraru
CNCarmen Neamtu
Carmen Neamtu
Background/Objectives: Organised colorectal cancer screening is still being introduced in Romania, and the yield of opportunistic colonoscopy outside it is poorly documented. Our primary aim was to describe the histopathological spectrum and the yield of advanced neoplasia in an opportunistic colonoscopy service; a secondary, exploratory aim was to describe self-reported lifestyle items in a questionnaire subgroup. Methods: This study represents a retrospective cross-sectional analysis of consecutive colonoscopies (June 2023–June 2024) at a county hospital outside organised screening, restricted to patients from whom material reached histopathology; the comparison group therefore comprises patients whose sampled lesions were benign, not patients without neoplasia. Advanced neoplasia was defined histologically as adenocarcinoma or adenoma with high-grade dysplasia, without the 10 mm size criterion. A convenience subgroup self-completed a locally developed, unvalidated questionnaire before the procedure; its items were tested against advanced neoplasia and adenocarcinoma with false discovery rate correction. Results: Among 274 patients, 45 (16.4%) had adenocarcinoma, 139 (50.7%) adenoma and 72 (26.3%) advanced neoplasia; per examination (n = 978), detection was 4.6% for adenocarcinoma and 7.4% for advanced neoplasia. Forty-four of 45 carcinomas were graded as moderately differentiated, and no serrated lesion was separately reported. Age was associated with advanced neoplasia (OR 1.34 per decade, 95% CI 1.01–1.79). Questionnaire data were available for only 79 patients (28.8%), among whom adenocarcinoma was more frequent than among non-respondents (26.6% vs. 12.3%). In this subgroup, obesity was inversely (OR 0.07, 95% CI 0.02–0.28) and reported weight loss positively (OR 6.77, 2.26–20.30) associated with advanced neoplasia, and two coffee items were inversely associated; processed meat, dairy, aspirin and supplement use were not associated after correction. Conclusions: Opportunistic colonoscopy at this centre recovered a high proportion of carcinoma, consistent with symptom-driven presentation, and the reporting of serrated lesions and tumour grade requires standardisation. The questionnaire findings rest on a small, selected subgroup and are hypothesis-generating only. The inverse obesity association is most plausibly explained by selection of the comparison group and of respondents, and none of the associations identifies a risk factor.

21 November 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
KOPPANDI OANAKOPPANDI OANA
KOPPANDI OANA
DIDana Iovanescu
Dana Iovanescu
BMBogdan Miutescu
Bogdan Miutescu
Eyad GadourEyad Gadour
Eyad Gadour
OJOana Maria Jigau
Oana Maria Jigau
EMEftimie Miutescu
Eftimie Miutescu
Background/Objectives: The Hepatitis C Virus (HCV) affects both physical health and overall well-being. The advent of direct-acting antivirals (DAAs) has greatly improved treatment outcomes. This study aimed to evaluate changes in quality of life (QoL) before and after DAA therapy. Methods: Ninety-seven patients with chronic HC were assessed using the SF-36v2 Health Survey, which measures eight physical and mental health domains. The questionnaire was administered at baseline (before treatment) and 12 weeks after achieving a sustained virological response (SVR). Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated. Results: Statistically significant improvements were observed across multiple domains, including Physical Functioning (mean increase: +3.99, p < 0.001), General Health (+5.51, p < 0.001), and Vitality (+4.44, p < 0.001). Both PCS and MCS scores improved after therapy, indicating enhanced overall well-being. Subgroup analyses suggested greater physical gains among older patients and those with cirrhosis. Conclusions: Successful HCV treatment with DAAs improves not only virological outcomes but also patients’ day-to-day functioning and emotional health. Routine integration of QoL assessments is essential to capture the full spectrum of benefits offered by modern antiviral therapy.